Genprex Business Summary

Genprex, Inc. (GNPX) is a clinical-stage biopharmaceutical company that operates on a research-driven business model, currently generating zero product revenue as it advances its pipeline toward commercialization. The company’s value proposition is centered on its proprietary, non-viral Oncoprex® Nanoparticle Delivery System, which facilitates the systemic administration of tumor suppressor genes. Genprex operates through two primary therapeutic segments: its oncology program, led by the Reqorsa® Immunogene Therapy for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), and its diabetes program, focused on the GPX-002 gene therapy. Positioned as a specialized innovator in the gene therapy market, Genprex competes with clinical-stage peers such as Evaxion A/S (EVAX), Adaptimmune Therapeutics (ADAP), and Exicure, Inc. (XCUR), distinguishing itself through its unique focus on restoring the p53 master regulator gene and its non-viral delivery platform. Originally co-founded in 2009 by the late David Nance and Rodney Varner, the company is currently led by Ryan M. Confer, who serves as President, Chief Executive Officer, and Chief Financial Officer. Confer brings over a decade of experience in technology commercialization and finance, having previously served as the company’s COO and CFO. The executive suite includes Chief Medical Officer Mark S. Berger, M.D., an oncology veteran with prior leadership roles at Actinium Pharmaceuticals and Kadmon Corporation, and Hemant Kumar, Ph.D., who serves as Chief Manufacturing and Technology Officer. The company’s strategic direction is bolstered by a high-pedigree advisory board featuring Nobel Laureate James E. Rothman, Ph.D., as a strategic advisor and Dr. Jack A. Roth of MD Anderson Cancer Center as Chairman of the Scientific Advisory Board. Notable institutional backing includes positions held by Armistice Capital, Geode Capital Management, and Susquehanna International Group.